These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 28472812)

  • 1. Agreement between Estimated and Measured Renal Function in an Everyday Clinical Outpatient Setting of Human Immunodeficiency Virus-Infected Individuals.
    Ahlström MG; Kjær A; Gerstoft J; Obel N
    Nephron; 2017; 136(4):318-327. PubMed ID: 28472812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporal changes in renal glomerular function associated with the use of Tenofovir Disoproxil Fumarate in HIV-infected Nigerians.
    Agbaji OO; Agaba PA; Idoko JA; Taiwo B; Murphy R; Kanki P; Ekong E
    West Afr J Med; 2011; 30(3):164-8. PubMed ID: 22120479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of Decline of Kidney Function in Human Immunodeficiency Virus-Infected Patients Under Routine Clinical Management.
    Boucquemont J; Lawson-Ayayi S; Rigothier C; Bonnet F; Proust-Lima C; Neau D; Greib C; Miremont-Salamé G; Dabis F; Dupon M; Dauchy FA;
    Nephron; 2017; 136(3):211-220. PubMed ID: 28445881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of tenofovir disoproxil fumarate-based antiretroviral therapy in an HIV-infected patient following unilateral nephrectomy.
    Biagi M; Badowski M; Chiampas T; Young J; Vaughn P; Shicker L; Patel M
    Int J STD AIDS; 2016 Aug; 27(9):808-11. PubMed ID: 26378193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal Toxicity of Concomitant Exposure to Tenofovir and Inhibitors of Tenofovir's Renal Efflux Transporters in Patients Infected With HIV Type 1.
    Rokx C; Alshangi H; Verbon A; Zietse R; Hoorn EJ; Rijnders BJ
    J Infect Dis; 2016 Feb; 213(4):561-8. PubMed ID: 26401025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.
    Quesada PR; Esteban LL; García JR; Sánchez RV; García TM; Alonso-Vega GG; Ferrández JS
    Int J Clin Pharm; 2015 Oct; 37(5):865-72. PubMed ID: 26008219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal function of participants in the Bangkok tenofovir study--Thailand, 2005-2012.
    Martin M; Vanichseni S; Suntharasamai P; Sangkum U; Mock PA; Gvetadze RJ; Curlin ME; Leethochawalit M; Chiamwongpaet S; Cherdtrakulkiat T; Anekvorapong R; Leelawiwat W; Chantharojwong N; McNicholl JM; Paxton LA; Kittimunkong S; Choopanya K;
    Clin Infect Dis; 2014 Sep; 59(5):716-24. PubMed ID: 24829212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.
    Goicoechea M; Liu S; Best B; Sun S; Jain S; Kemper C; Witt M; Diamond C; Haubrich R; Louie S;
    J Infect Dis; 2008 Jan; 197(1):102-8. PubMed ID: 18171292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of kidney function in HIV-infected patients receiving an antiretroviral regimen containing one or two inhibitors of the tubular secretion of creatinine.
    Casado JL; Monsalvo M; Vizcarra P; Fontecha M; Serrano-Villar S; Moreno S
    HIV Med; 2019 Nov; 20(10):648-656. PubMed ID: 31321875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cystatin C- and creatinine-based equations in the assessment of renal function in HIV-positive patients prior to commencing Highly Active Antiretroviral Therapy.
    Seape T; Gounden V; van Deventer HE; Candy GP; George JA
    Ann Clin Biochem; 2016 Jan; 53(Pt 1):58-66. PubMed ID: 25766385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of tenofovir disoproxil fumarate on kidney function: four-year data from the HIV-infected outpatient cohort.
    Monteiro N; Branco M; Peres S; Borges F; Mansinho K
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19565. PubMed ID: 25394072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV Infection, Tenofovir, and Urine α1-Microglobulin: A Cross-sectional Analysis in the Multicenter AIDS Cohort Study.
    Jotwani V; Scherzer R; Estrella MM; Jacobson LP; Witt MD; Palella FJ; Macatangay B; Bennett M; Parikh CR; Ix JH; Shlipak MG
    Am J Kidney Dis; 2016 Oct; 68(4):571-581. PubMed ID: 27287300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial.
    Decloedt EH; Lesosky M; Maartens G; Joska JA
    AIDS Res Ther; 2017 Feb; 14(1):6. PubMed ID: 28160772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
    Palacios R; Hidalgo C; Ríos MJ; Rivero A; Muñoz L; Lozano F; Gutiérrez-Ravé V; Gálvez MC; del Arco A; Santos J
    Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):399-402. PubMed ID: 18841401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy.
    Winston A; Amin J; Mallon P; Marriott D; Carr A; Cooper DA; Emery S
    HIV Med; 2006 Mar; 7(2):105-11. PubMed ID: 16420255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients.
    Biagi M; Badowski ME; Chiampas T; Young J; Patel M; Vaughn P
    Int J STD AIDS; 2017 Jul; 28(8):766-772. PubMed ID: 27587601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High prevalence of signs of renal damage despite normal renal function in a cohort of HIV-infected patients: evaluation of associated factors.
    Bonjoch A; Juega J; Puig J; Pérez-Alvarez N; Aiestarán A; Echeverría P; Pérez V; Clotet B; Romero R; Bonet J; Negredo E
    AIDS Patient Care STDS; 2014 Oct; 28(10):524-9. PubMed ID: 25238104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up.
    Nishijima T; Kawasaki Y; Tanaka N; Mizushima D; Aoki T; Watanabe K; Kinai E; Honda H; Yazaki H; Tanuma J; Tsukada K; Teruya K; Kikuchi Y; Gatanaga H; Oka S
    AIDS; 2014 Aug; 28(13):1903-10. PubMed ID: 25259702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenofovir disoproxil fumarate-associated hypophosphatemia as determined by fractional excretion of filtered phosphate in HIV-infected patients.
    Cheng CY; Chang SY; Lin MH; Ku SY; Sun NL; Cheng SH
    J Infect Chemother; 2016 Nov; 22(11):744-747. PubMed ID: 27613487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel antiretroviral drugs and renal function monitoring of HIV patients.
    Maggi P; Montinaro V; Mussini C; Di Biagio A; Bellagamba R; Bonfanti P; Calza L; Cherubini C; Corsi P; Gargiulo M; Montella F; Rusconi S
    AIDS Rev; 2014; 16(3):144-51. PubMed ID: 25102336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.